Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CARDINAL HEALTH, INC.

(CAH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cardinal to buy J&J vascular technology unit Cordis for $1.9 billion

03/02/2015 | 12:49pm EDT

NEW YORK (Reuters) - U.S. pharmaceutical and medical equipment maker Johnson & Johnson (>> Johnson & Johnson) said on Monday it agreed to sell its Cordis vascular technology unit to Cardinal Health (>> Cardinal Health Inc) for $1.9 billion (1.2 billion pounds), completing its exit from the cardiovascular stent business.

NEW YORK (Reuters) - U.S. pharmaceutical and medical equipment maker Johnson & Johnson (>> Johnson & Johnson) said on Monday it agreed to sell its Cordis vascular technology unit to Cardinal Health (>> Cardinal Health Inc) for $1.9 billion (1.2 billion pounds), completing its exit from the cardiovascular stent business.

Cardinal, one of the largest U.S. drug distribution companies, is expanding its medical equipment offerings for physicians.

"While this transaction is not without obvious risks and does mark a change in CAH's overall business mix/business model, we believe the financial attractiveness outweighs this fact," Evercore ISI analyst Ross Muken said in a research note.

Cardinal, which expects the deal to close by the end of calendar year 2015, said the acquisition will be slightly dilutive to earnings in the fiscal year ending June 2016. It expects the deal to then boost earnings by 20 cents per share in the fiscal year ending June 30, 2017, and it sees cost savings of $100 million by the end of fiscal 2018.

Cardinal's chief executive, George Barrett, said the company may make more acquisitions in cardiology and endovascular treatment as well as in the trauma and wound care segment.

"Those are areas where we could see opportunities to fill out the portfolio," Barrett said in an interview.

Shares of Cardinal rose 1.4 percent, or $1.24, to $89.23, in early afternoon trading, while J&J rose 0.6 percent, or 64 cents, to $103.15.

J&J, which makes pharmaceuticals, medical equipment and consumer items, said it will still own its electrophysiology business and the drug Xarelto in the cardiovascular segment.

It exited the highly competitive drug-coated stent market four years ago because it was not a top player and faced competition from Medtronic Plc (>> Medtronic PLC), Abbott Laboratories (>> Abbott Laboratories), St Jude Medical Inc (>> St. Jude Medical, Inc.) and Boston Scientific Corp (>> Boston Scientific Corporation).

Cordis gets about 70 percent of its revenue from outside the United States, and its principal markets include Europe, China, and Japan.

The Cordis business includes wires and guides and other equipment used in cardiology and endovascular procedures. The latter includes products to treat aneurysms and to open up arteries such as in the abdominal aorta.

Cardinal was advised by Wachtell, Lipton, Rosen and Katz and Jones Day and by Goldman Sachs Group (>> Goldman Sachs Group Inc). J&J was advised by Cravath, Swaine & Moore LLP and Baker & McKenzie LLP and JP Morgan Chase (>> JPMorgan Chase & Co.).

(Reporting by Caroline Humer; Editing by Leslie Adler)

By Caroline Humer


ę Reuters 2015
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 0.47% 121.09 Delayed Quote.10.07%
BOSTON SCIENTIFIC CORPORATION -0.24% 45.32 Delayed Quote.26.37%
CARDINAL HEALTH, INC. 0.57% 59.99 Delayed Quote.10.94%
EVERCORE INC. 1.55% 134.01 Delayed Quote.20.37%
JOHNSON & JOHNSON 0.00% 172.18 Delayed Quote.9.40%
MEDTRONIC PLC 0.12% 130.68 Delayed Quote.11.42%
THE GOLDMAN SACHS GROUP, INC. 0.89% 377.55 Delayed Quote.41.91%
All news about CARDINAL HEALTH, INC.
07/28CARDINAL HEALTH : Trial against opioid distributors wraps up in West Virginia
AQ
07/27W. Va. city, drug distributors trade final words in landmark opioid trial
RE
07/27AMERISOURCEBERGEN : Closing arguments held in West Virginia lawsuit over opioids
AQ
07/27Frontline advocates view $26 billion opioid deal with frustration, worry
RE
07/22ENDO INTERNATIONAL : Drugmaker Endo settles opioid claims by Tennessee counties,..
RE
07/22CARDINAL HEALTH : DISTRIBUTORS ANNOUNCE PROPOSED OPIOID SETTLEMENT AGREEMENT (Fo..
PU
07/22CARDINAL HEALTH INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/21U.S. state officials urge support for landmark $26 billion opioid settlement
RE
07/21CARDINAL HEALTH : States reach $26B opioid settlement with Johnson & Johnson, 'b..
AQ
07/21Health Care Flat As Traders Hedge On Growth View -- Health Care Roundup
DJ
More news
Financials (USD)
Sales 2021 160 B - -
Net income 2021 652 M - -
Net Debt 2021 3 091 M - -
P/E ratio 2021 27,1x
Yield 2021 3,27%
Capitalization 17 406 M 17 406 M -
EV / Sales 2021 0,13x
EV / Sales 2022 0,12x
Nbr of Employees 48 000
Free-Float 88,8%
Chart CARDINAL HEALTH, INC.
Duration : Period :
Cardinal Health, Inc. Technical Analysis Chart | CAH | US14149Y1082 | MarketScreener
Technical analysis trends CARDINAL HEALTH, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 59,99 $
Average target price 62,08 $
Spread / Average Target 3,48%
EPS Revisions
Managers and Directors
Michael C. Kaufmann Chief Executive Officer & Director
Jason M. Hollar Chief Financial Officer
Gregory B. Kenny Independent Non-Executive Chairman
Brian S. Rice Chief Information Officer & Executive VP
Jessica L. Mayer Chief Compliance & Legal Officer
Sector and Competitors